“研究数据强调的是,人们需要认识到,这种检测的结果可能不会是错误的,但遗憾的是,它们是不完整的。”
The research also showed that those from Asian and African-American backgrounds were more likely to carry mutations that were not designed to be detected by the consumer tests.
这项研究还表明,有亚裔和非洲裔血统的美国人更有可能携带突变基因,而消费者测试无法检测到这些突变基因。
The research focused on DNA-based tests relating to breast, ovarian and bowel cancer that were recently approved by the US Food and Drug Administration.
这项研究的重点是美国食品和药物管理局(FDA)最近批准的与乳腺癌、卵巢癌和肠癌相关的DNA检测。
The tests operate by a subject sending a DNA swab in the post for analysis and then receiving results with information about how their genetics could influence their health.
测试是这样进行的:受试者寄送DNA样本用于分析,然后收到有关基因对健康影响的检测结果。
In the case of breast and ovarian cancer, the FDA has approved a screening test for three specific mutations on the BRCA1 and BRCA2 genes, which are most common in people of Ashkenazi Jewish heritage. However, these mutations are rare in people from other backgrounds.
就乳腺癌和卵巢癌而言,FDA已经批准了一项针对BRCA1和BRCA2基因三种特定突变的筛查测试,这两种突变在德系犹太人中最为常见。然而,这些突变在其他血统的人身上很少见。
【基因检测结果呈阴性可能是"虚假的安慰"】相关文章:
最新
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15